Asian Pricing and Reimbursement
Ju Hyoung Lim, MSc, Ph.D.
How to compete and succeed in a rapidly changing market
A land of pharma opportunity and financial challenges
Growing major trends are emerging across Asian healthcare markets. Rising incomes, increased government healthcare expenditure, higher life expectancies and a surge of chronic illnesses are boosting the demand for pharmaceutical products and services in the region. This sea of change is also being driven by multiple factors including government healthcare reforms, increasing Universal Health Coverage (UHC), the rise of private financing and heavy promotion of the generic market.
This offers a significant opportunity both for established pharmaceutical companies in the region who wish to continue to thrive and for those considering entering the Asian market. However, it also presents a unique set of regional challenges and commercial success will be dependent on understanding the complexities of the Asian pricing and reimbursement environment.
Opportunities within a changing Asian market
The Asian healthcare landscape is a dynamic one. The region consists of a wide diversity of healthcare markets in very different stages of development, particularly with regard to their healthcare infrastructure.
The healthcare environment within Asia is changing dramatically and spending in the region has shown an explosive rise in recent decades. Between 2009-2012 Asian markets showed the highest growth of per-capita healthcare spending in the world, at 38.8% of CAGR compared with the global average of 26.3%.1 The sharp increase of healthcare spending in this region can be explained by several factors, including growing economies, expansion of the middle class, the rise of chronic illness and increased life expectancy.
To meet this rapid growth, Asian healthcare systems will need to expand and adapt. As more countries implement healthcare reforms, leading to greater patient population coverage, countries across Asia will need to address pricing and reimbursement challenges to meet healthcare demands.
Ju Hyoung Lim, MSc, Ph.D.
Dr. Ju Hyoung Lim has extensive expertise within the Asian pharmaceutical market. He has an expert knowledge of pricing and reimbursement, biosimilar development and competition, and various therapeutic areas including Oncology, Autoimmune, and Infectious Diseases. Dr. Lim received his doctoral degree in microbiology from KAIST (Korea Advanced Institute of Science and Technology), and worked as a postdoctoral fellow at MIT (Massachusetts Institute of Technology) in Boston, USA. He has been with Deallus for over 5 years and currently holds the position of Senior Manager in Singapore.
We are excited to announce that Gloria Kwon has joined our Deallus team as a Senior Principal based out of our Los Angeles office. Gloria comes to Deallus with significant experience in business strategy, product commercialization and operational excellence for pharmaceutical and biotechnology companies. Prior to joining Deallus, Gloria spent over 8 years at Navigant Consulting.
Deallus is pleased to announce that Peter Barschdorff is joining the organization as Vice President, leading its U.S. consulting business, with offices in Los Angeles and New York. Peter has held leadership positions in a number of management consulting organizations and has built innovative enterprise capabilities in commercial pharma.
Jonas gives a keynote speech that delves into the importance of strategic intelligence for pharma given today’s dynamic and disruptive marketplace. He explores how competitive and strategic intelligence are related, how to build more strategically focused engagements, and how to help decision makers realize the value in strategic partnerships with their intelligence teams.
Jonas fields questions about his keynote speech, further exploring what strategic intelligence means for pharma and how it can add value.